keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/28100192/design-and-rationale-of-a-large-international-prospective-cohort-study-to-evaluate-the-occurrence-of-malformations-and-perinatal-neonatal-death-using-insulin-detemir-in-pregnant-women-with-diabetes-in-comparison-with-other-long-acting-insulins
#1
Elisabeth R Mathiesen, Henning Andersen, Sofia I I Kring, Peter Damm
BACKGROUND: There are a lack of data regarding the effect of basal insulin analogues on rates of events like congenital malformation and perinatal mortality in diabetic pregnancy. METHODS: The present study is a prospective, non-interventional, multicentre cohort study conducted in seven countries, designed to assess the safety of insulin detemir during pregnancy, and to monitor the health status of resulting infants (exposed in utero) up to 1 year of age. The study population includes women with type 1 or type 2 diabetes, who are pregnant and being treated with insulin...
January 18, 2017: BMC Pregnancy and Childbirth
https://www.readbyqxmd.com/read/28099755/comparing-effects-of-insulin-analogues-and-human-insulin-on-nocturnal-glycaemia-in-hypoglycaemia-prone-people-with-type-1-diabetes
#2
P L Kristensen, L Tarnow, C Bay, K Nørgaard, T Jensen, H-H Parving, H Perrild, H Beck-Nielsen, J S Christiansen, B Thorsteinsson, U Pedersen-Bjergaard
AIMS: To assess the difference between analogue and human insulin with regard to nocturnal glucose profiles and risk of hypoglycaemia in people with recurrent severe hypoglycaemia. METHODS: A total of 72 people [46 men, mean ± sd age 54 ± 12 years, mean ± sd HbA1c 65 ± 12 mmol/mol (8.1 ± 1.1%), mean ± sd duration of diabetes 30 ± 14 years], who participated in a 2-year randomized, crossover trial of basal-bolus therapy with insulin detemir/insulin aspart or human NPH insulin/human regular insulin (the HypoAna trial) were studied for 2 nights during each treatment...
January 18, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28096223/combination-therapy-with-exenatide-plus-pioglitazone-versus-basal-bolus-insulin-in-poorly-controlled-patients-with-type-2-diabetes-on-sulfonylurea-plus-metformin-the-qatar-study
#3
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi
OBJECTIVE: The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal-bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. RESEARCH DESIGN AND METHODS: The study randomized 231 patients with poorly controlled (HbA1c >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive 1) pioglitazone plus weekly exenatide (combination therapy), or 2) basal plus prandial insulin (insulin therapy) to maintain HbA1c <7...
January 17, 2017: Diabetes Care
https://www.readbyqxmd.com/read/28095372/impaired-mitochondrial-respiration-in-large-cerebral-arteries-of-rats-with-type-2-diabetes
#4
Ivan Merdzo, Ibolya Rutkai, Venkata N L R Sure, Catherine A McNulty, Prasad V G Katakam, David W Busija
Mitochondrial dysfunction has been suggested as a potential underlying cause of pathological conditions associated with type 2 diabetes (T2DM). We have previously shown that mitochondrial respiration and mitochondrial protein levels were similar in the large cerebral arteries of insulin-resistant Zucker obese rats and their lean controls. In this study, we extend our investigations into the mitochondrial dynamics of the cerebral vasculature of 14-week-old Zucker diabetic fatty obese (ZDFO) rats with early T2DM...
January 18, 2017: Journal of Vascular Research
https://www.readbyqxmd.com/read/28091878/insulin-degludec-in-clinical-practice-a-review-of-japanese-real-world-data
#5
Kohei Kaku, Michael Lyng Wolden, Jacob Hyllested-Winge, Emil Nørtoft
INTRODUCTION: In this literature review we evaluated the real-world clinical effectiveness of switching Japanese diabetic patients from their current insulin regimen to insulin degludec (IDeg). METHODS: Studies were identified from Japanese Diabetes Society (JDS) abstracts (2014-2015) and PubMed (2012 onwards). Inclusion criteria were: Japanese population, >15 participants, and studies switching patients from basal or basal-bolus insulin regimens to IDeg. Randomized controlled trials and case reports were excluded...
January 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28077204/review-of-the-next-generation-of-long-acting-basal-insulins-insulin-degludec-and-insulin-glargine
#6
Matthew Stailey, Susan E Conway
Older adults are at an increased risk of developing type 2 diabetes mellitus (T2DM). Although oral agents (i.e., metformin) are the preferred first-line therapy, older adults often eventually require the addition of insulin to control their blood glucose. Long-acting insulin analogues are the preferred insulin products for older adults with T2DM. Insulin degludec and insulin glargine U-300 are both new generation long-acting insulins. When compared with the standard of care, long-acting insulin product insulin glargine U-100, insulin degludec, and insulin glargine U-300 had similar glucose-lowering effects, longer half-lives and durations of action, and a more even distribution over a 24-hour period...
January 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28067472/efficacy-of-basal-bolus-insulin-regimens-in-the-inpatient-management-of-non-critically-ill-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#7
REVIEW
Merete B Christensen, Anders Gotfredsen, Kirsten Nørgaard
BACKGROUND: Hyperglycemia during hospitalization is associated with increased rates of complications and longer hospital stays. Various insulin regimens are used in the inpatient diabetes management of non-critically ill patients. We aimed to assess the efficacy and safety of basal-bolus insulin therapy (BBI) by summarizing evidence from studies of BBI versus sliding scale insulin therapy (SSI) in the management of hospitalized non-critically ill type 2 diabetes patients. METHODS: We searched MEDLINE, EMBASE, Scopus and the Cochrane Library for studies comparing BBI therapy with SSI therapy in hospitalized non-critically ill patients with type 2 diabetes...
January 9, 2017: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/28063135/cost-effectiveness-of-insulin-degludec-plus-liraglutide-ideglira-in-a-fixed-combination-for-uncontrolled-type-2-diabetes-mellitus-in-sweden
#8
Åsa Ericsson, Adam Lundqvist
BACKGROUND: Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia. OBJECTIVE: This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy(®)) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin. METHODS: The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective...
January 6, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28061430/exploring-the-characteristics-of-suboptimally-controlled-patients-after-24weeks-of-basal-insulin-treatment-an-individualized-approach-to-intensification
#9
Kamlesh Khunti, Taner Damci, Lise Lotte Husemoen, Vinay Babu, Andreas Liebl
AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on basal insulin treatment who may benefit from intensive titration or further intensification of treatment. METHODS: A post hoc analysis of SOLVE: a 24-week, international, observational study conducted in 17,374 patients with T2DM inadequately controlled on oral antidiabetic drugs (OADs) started on once-daily insulin detemir. Patients were divided into two groups based on whether they achieved HbA1c<7...
December 9, 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28058800/basal-rate-tests-24-h-fasts-performed-in-type-1-diabetic-subjects-with-either-absolute-fasting-or-snacks-containing-negligible-carbohydrate-amounts-result-in-similar-glucose-profiles-a-randomized-controlled-prospective-trial
#10
Maike Haase, Melanie Kahle, Martin Janert, Juris J Meier, Michael A Nauck
AIMS/HYPOTHESIS: Basal rate tests (24 h fasting periods) may be necessary to optimize basal insulin replacement in type 1 diabetes. It was the aim to prospectively compare allowing negligible carbohydrate snacks versus absolute fasting. METHODS: 20 patients with type 1 diabetes (age 48 ± 15 years; 9 women, 11 men; BMI 28.5 ± 4.5 kg/m(2) ; HbA1c 8.8 ± 2.0 % (73.0 ± 21.9 mmol/mol); insulin dose 0.69 ± 0.31 IU/kg body weight and day) participated in two basal rate tests lasting 24 h in random order with unchanged basal insulin replacement...
January 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28053550/real-world-medication-persistence-and-outcomes-associated-with-basal-insulin-and-glucagon-like-peptide-1-receptor-agonist-free-dose-combination-therapy-in-patients-with-type-2-diabetes-in-the-us
#11
Jay Lin, Melissa Lingohr-Smith, Tao Fan
BACKGROUND: Free-dose combination treatment with basal insulin and short-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduces hyperglycemia via complementary targeting of fasting and postprandial blood glucose levels, however, in the real world, due to injection burden and clinical inertia, the full efficacy may not be able to translate into clinical and economic benefits. OBJECTIVE: The aim of the study was to evaluate treatment persistence and associated outcomes in patients with type 2 diabetes (T2D) treated with a GLP-1 RA in free-dose combination with basal insulin...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28035840/cost-effectiveness-of-switching-to-insulin-degludec-from-other-basal-insulins-evidence-from-swedish-real-world-data
#12
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson, Susanne Ellfors-Zetterlund
OBJECTIVES: Health economic analysis from a health care and societal point of view was conducted to assess cost-effectiveness of insulin degludec (IDeg) after switching from other basal insulins in people with type 1 diabetes. MATERIAL AND METHODS: This was a prospective, open-label, single arm, observational follow-up from August 2013-October 2015 of 476 consecutive patients at Danderyd Hospital [Stockholm, Sweden] who switched to IDeg from other basal insulins (99% basal insulin analogs)...
December 30, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28031780/double-diabetes-in-saudi-arabia-a-new-entity-or-an-underestimated-condition
#13
Rim Braham, Aus Alzaid, Asirvatham Alwin Robert, Muhammad Mujammami, Rania Ahmad Ahmad, Monther Zitouni, Samia Hasan Sobki, Mohamed Abdulaziz Al Dawish
AIM: To determine the clinical and biological characteristics of double diabetes (DD) among young people in Saudi Arabia. METHODS: This was a retrospective descriptive chart review study including 312 young newly diagnosed diabetic patients (aged 12-20 years), whom were admitted over a five year period (January 2009 to December 2013). Family history of diabetes mellitus (DM) (first degree), physical body mass index (BMI), acanthosis nigricans, history of auto-immune disease and laboratory information for glycosylated hemoglobin, basal C peptide level and diabetes autoantibody response (anti-GAD, anti-IA2 and anti-ICA) were collected from medical report...
December 15, 2016: World Journal of Diabetes
https://www.readbyqxmd.com/read/28029018/exenatide-versus-insulin-lispro-added-to-basal-insulin-in-a-subgroup-of-korean-patients-with-type-2-diabetes-mellitus
#14
Kun Ho Yoon, Elise Hardy, Jenny Han
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in Korea. Clinical studies in patients with T2DM have shown that combining the glucagon-like peptide-1 receptor agonist exenatide twice daily with basal insulin is an effective glucose-lowering strategy. However, these studies were predominantly conducted in non-Asian populations. METHODS: We conducted a subgroup analysis of data from a multinational, 30-week, randomized, open-label trial to compare the effects of exenatide twice daily (n=10) or three times daily mealtime insulin lispro (n=13) among Korean patients with T2DM inadequately controlled (glycosylated hemoglobin [HbA1c] >7...
December 26, 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28027979/the-impairment-of-glucose-stimulated-insulin-secretion-in-pancreatic-%C3%AE-cells-caused-by-prolonged-glucotoxicity-and-lipotoxicity-is-associated-with-elevated-adaptive-antioxidant-response
#15
Jingqi Fu, Qi Cui, Bei Yang, Yongyong Hou, Huihui Wang, Yuanyuan Xu, Difei Wang, Qiang Zhang, Jingbo Pi
Type 2 diabetes (T2D) is a progressive disease characterized by sustained hyperglycemia and is frequently accompanied by hyperlipidemia. Deterioration of β-cell function in T2D patients may be caused, in part, by long-term exposure to high concentrations of glucose and/or lipids. We developed systems to study how chronic glucotoxicity and lipotoxicity might be linked to the impairment of glucose-stimulated insulin secretion (GSIS) machinery in pancreatic β-cells. INS-1 (832/13) were exposed to glucose and/or palmitate for up to 10 weeks...
December 25, 2016: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/28017449/anabolic-resistance-does-not-explain-sarcopenia-in-patients-with-type-2-diabetes-mellitus-compared-with-healthy-controls-despite-reduced-mtor-pathway-activity
#16
Daniel J Cuthbertson, John Babraj, Graham Leese, Mario Siervo
BACKGROUND: Ageing and type 2 diabetes mellitus (T2DM) are risk factors for skeletal muscle loss. We investigated whether anabolic resistance to feeding might underlie accelerated muscle loss in older people with T2DM and whether dysregulated mTOR signalling was implicated. SUBJECTS: 8 obese men with T2DM, and 12 age-matched controls were studied (age 68 ± 3 vs. 68±6 y; BMI: 30 ± 2 vs. 27 ± 5 kg m(-2)). METHODS: Body composition was measured by dual-X-ray absorptiometry...
November 25, 2016: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28008768/the-cost-effectiveness-of-dulaglutide-versus-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-in-spain-in-patients-with-bmi%C3%A2-30%C3%A2-kg-m-2
#17
Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, Ruba Ayyub, Julia Lowin, Kirsi Norrbacka
OBJECTIVE: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 (GLP-1) receptor agonist, for the treatment of type two diabetes mellitus (T2DM). The objective was to estimate the cost-effectiveness of dulaglutide once weekly versus liraglutide 1.8mg once daily for the treatment of T2DM in Spain in patients with a BMI≥30 kg/m(2). METHODS: The IMS CORE Diabetes Model (CDM) was used to estimate costs and outcomes from the perspective of Spanish National Health System, capturing relevant direct medical costs over a lifetime time horizon...
December 23, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27997217/investigating-hypoglycemic-confidence-in-type-1-and-type-2-diabetes
#18
William H Polonsky, Lawrence Fisher, Danielle Hessler, Steven V Edelman
BACKGROUND: While research designed to understand the concerns about hypoglycemia among patients with diabetes has been primarily focused on the investigation of fear and anxiety, recent evidence suggests a potentially important and conceptually distinct element-hypoglycemic confidence. To investigate this dimension, we developed the Hypoglycemic Confidence Scale (HCS); herein, we describe the construction and validation of the HCS and examine how key patient factors are associated with hypoglycemic confidence...
December 20, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27988180/factors-associated-with-reaching-or-not-reaching-target-hba1c-after-initiation-of-basal-or-premixed-insulin-in-patients-with-type-2-diabetes
#19
A J Scheen, H Schmitt, H H Jiang, T Ivanyi
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1c) levels by analysing the respective contributions of fasting hyperglycaemia (FHG), also referred to as basal hyperglycaemia, vs postprandial hyperglycaemia (PHG) before and after initiation of a basal or premixed insulin regimen in patients with type 2 diabetes. METHODS: This post-hoc analysis of insulin-naïve patients in the DURABLE study randomised to receive either insulin glargine or insulin lispro mix 25 evaluated the percentages of patients achieving a target HbA1c of <7...
December 14, 2016: Diabetes & Metabolism
https://www.readbyqxmd.com/read/27986406/addition-of-once-daily-prandial-lixisenatide-to-basal-insulin-therapy-in-patients-with-type-2-diabetes-results-in-a-reduction-of-hba1c-as-an-effect-of-postprandial-glucose-lowering
#20
Holger Fleischmann, Rüdiger Göke, Peter Bramlage
AIMS: Basal insulin has been shown to effectively reduce fasting blood glucose (FBG), but postprandial plasma glucose (PPG) excursions may remain higher than normal. Glucagon-like peptide (GLP)-1 receptor agonists such as the short-acting lixisenatide are able to control such excursions by slowing gastric emptying. However, data regarding its use in a real world clinical setting are scarce. METHODS: 24 week, prospective, multicentre, non-interventional study in 1437 patients with type-2 diabetes receiving 20μg lixisenatide once daily in combination with basal insulin...
December 12, 2016: Diabetes & Metabolic Syndrome
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"